Atomoxetine for attention deficit/hyperactivity disorder
Garces K
Record ID 32003000472
English, French
Authors' objectives:
To summarise the available evidence on atomoxetine (ATX) for attention deficit/hyperactivity disorder.
Authors' recommendations:
- Seven randomized, double-blinded, controlled trials in children, adolescents and adults have shown that atomoxetine improves attention deficit/hyperactivity disorder (ADHD) symptoms compared to placebo.
- There is no evidence that atomoxetine has greater efficacy or a better safety profile than currently used therapy.
- Atomoxetine has been submitted for regulatory approval in Canada and is currently approved in the US. The price of atomoxetine in Canada has not been established.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2003
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Costs and Cost Analysis
- Attention Deficit Disorder with Hyperactivity
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.